GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · IEX Real-Time Price · USD
0.284
-0.012 (-3.98%)
At close: Jul 19, 2024, 4:00 PM
0.285
+0.001 (0.18%)
Pre-market: Jul 22, 2024, 7:33 AM EDT
GlycoMimetics Revenue
GlycoMimetics had revenue of $10.00K in the twelve months ending March 31, 2024. In the year 2023, GlycoMimetics had annual revenue of $10.00K.
Revenue (ttm)
$10.00K
Revenue Growth
-86.67%
P/S Ratio
1,833.37
Revenue / Employee
$286
Employees
35
Market Cap
18.33M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
Dec 31, 2020 | 10.16M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 18.50K | -20.05M | -99.91% |
Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
Dec 31, 2012 | 15.26M | 11.44M | 300.04% |
Dec 31, 2011 | 3.81M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MEI Pharma | 66.75M |
Cara Therapeutics | 16.94M |
Biotricity | 12.06M |
Aspira Women's Health | 8.99M |
Synlogic | 3.21M |
Aeterna Zentaris | 2.37M |
iBio, Inc. | 50.00K |
GLYC News
- 6 weeks ago - GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire
- 7 weeks ago - GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 - Business Wire
- 2 months ago - GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire
- 3 months ago - GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 4 months ago - GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 - Business Wire
- 4 months ago - GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 - Business Wire
- 5 months ago - GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference - Business Wire
- 5 months ago - GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire